Terminated PHASE3 INTERVENTIONAL 2-arm NCT00072215

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Extragonadal Germ Cell Tumor Testicular Germ Cell Tumor

Interventions cisplatin ifosfamide paclitaxel vinblastine

Updated 7 times since 2017 Last updated: Jul 1, 2016 Started: Apr 30, 2004 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

poor accrual

Other terminated trials from Alliance for Clinical Trials in Oncology

See all terminations from Alliance for Clinical Trials in Oncology

Listed as NCT00072215, this PHASE3 trial focuses on Extragonadal Germ Cell Tumor and Testicular Germ Cell Tumor and remains terminated or withdrawn. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Asheville, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Burlington, United States , Camden, United States , Chapel Hill, United States , Charlottesville, United States , Chicago, United States and 51 more locations